ÂÜÀòÂÒÂ×

Richard Huckle is a seasoned professional in regulatory affairs with extensive experience in expediting access to rare disease therapies. Currently serving in a regulatory role at Healx since December 2020, Richard focuses on orphan drug designations and regulatory strategies for rare disease treatments. Richard has also held voluntary editorial responsibilities at TOPRA, and previously worked as a managing consultant at Osiris Pharma, where expertise in regulatory strategy accelerated product development. Prior positions include director of global regulatory affairs at Huron and senior consultant roles at Gregory Fryer Associates and PPD, contributing to successful clinical trial submissions and regulatory consultations. With an academic background in toxicology and pharmacology from the University of Hertfordshire, Richard has established a robust career in navigating complex regulatory landscapes.